Today's Rundown Gilead’s filgotinib fails midphase tests in lupus, Sjogren's Kronos Bio nabs Gilead, Baylor College of Medicine researchers Syros links SY-1425 combo to 50%-plus AML complete response rate [Sponsored] Advancing Site-Sponsor Relationships U.K. team sheds light on how AnaptysBio's anti-IL-33 eczema drug tamps down inflammation EuroBiotech Report—UCB beats J&J, Novartis fail, AstraZeneca, NASH deal and Evotec FiercePharmaAsia—Novartis’ generics deal, Zolgensma decision delays; AZ’s China performance Chutes & Ladders—Eli Lilly diabetes head Conterno set to step down Featured Story | | | Friday, October 25, 2019 A clutch of Gilead drugs including filgotinib have failed to move the needle in midphase clinical trials of cutaneous lupus and Sjogren's syndrome patients. Neither trial hit the primary endpoint, although Gilead did see “evidence of activity” in patients taking filgotinib. |
|
|---|
|
Top Stories Thursday, October 24, 2019 Fierce 15 winner Kronos Bio has hired two new research program execs as it looks to put its recent funding haul to work. Friday, October 25, 2019 Syros Pharmaceuticals has posted updated clinical data on SY-1425 in acute myeloid leukemia (AML). Seven of the 13 newly diagnosed AML patients with a certain biomarker had full complete responses after receiving the RARα agonist in combination with Celgene’s Vidaza. Monday, October 21, 2019 Clinical trials involve massive complexity and, often, systems that lack consistency and discipline. With a new perspective to an old problem, WCG coordinates the execution of six proven strategies to dramatically and consistently bring clinical studies to launch faster and at a lower cost. Thursday, October 24, 2019 AnaptysBio's etokimab, which targets IL-33, works by altering how immune cells that cause inflammation respond to allergens, researchers discovered by testing the skin of patients in a phase 2 trial. Thursday, October 24, 2019 In this week's EuroBiotech Report, UCB's bispecific beats J&J's Stelara, AstraZeneca dumps phase 3 cancer program and Novartis fails pivotal test. Friday, October 25, 2019 Sandoz's $1 billion U.S. generics deal with India's Aurobindo Pharma is delayed by FTC review. Decisions for Novartis' Zolgensma in EU and Japan are pushed back due to manufacturing questions. AstraZeneca expects mid-teens sales growth from China in the mid-term. And more. Friday, October 25, 2019 Eli Lilly diabetes chief Conterno will step down; MD Anderson's Hahn likely pick for FDA head; Amgen CFO Meline bows out. | | Better than the other transgenics.
Better than in vitro display.
Better than humanization. AlivaMabTM Mouse from Ablexis delivers quality, speed and value in generating development-ready antibodies that meet your target product profile. Contact us at info@ablexis.com to learn more. ablexis.com |
Resources Sponsored by: Outer Edge Technology Companies that don’t have a cloud strategy are at a competitive disadvantage. Why? The cloud has a measurable impact on business. Sponsored by: Medidata Simplified filing, improved oversight, audit readiness: is your eTMF system delivering best-in-class benefits? Sponsored by: Colorcon® Learn about how you better manage product authentication and battle drug counterfeiting with innovative solutions. Sponsored by: Cortellis, a Clarivate Analytics Solution Download this report for full details of Life sciences M&As in the second quarter of 2019 with notes and trends. Sponsored by: Elligo Health Research Find out how it leverages real-world data and novel IntElligo Research Stack™ technology to help researchers battle rising costs, cumbersome processes, and stagnant participation — bridging the gap between research and care. Sponsored by: InformedDNA Download this complimentary guide paper that explores key strategies for a successful genetics-informed clinical trial. Sponsored by: Life Image The time has finally come when medical imaging can be effectively utilized into the RWE process. Read the whitepaper on the best practices for incorporating Real World Imaging.™ Sponsored by: Patheon, by Thermo Fisher Scientific Is your API development on track? Sponsored by: ON24 Compare digital program performance and audience engagement among your life sciences peers. Sponsored by: Decision Resources Group Clinically Integrated Networks are vehicles for powerful IDNs to extend their influence into the physician sector and play a key role for IDNs trying to pave a path to becoming a self-contained healthcare ecosystem. Sponsored by: Roche and IQVIA A global landscape study of funding trends and innovations. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. 4th FierceBiotech Drug Development Forum October 28-29, 2019 | Boston, MA Drug Development Immersion November 7-8, 2019 | Boston, MA Advanced Therapies: Immunotherapies, Cell Therapies and Gene Therapies November 15, 2019 | Boston, MA Countdown to Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register Now at www.drugstomarket.com/drugbootcamp and start Pre-Boot Camp Preparation | 